NEW YORK (GenomeWeb) – HTG Molecular Diagnostics reported on Tuesday a 5 percent drop in second quarter revenues as a decline in consumable sales more than offset an increase in revenues from biopharmaceutical partners.

For the three-month period ended June 30, HTG's revenues slipped to $1.8 million from $1.9 million in the same quarter last year. Service revenues grew to $1.4 million from $1.3 million, while product revenues fell to $407,177 from $577,127.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.